SUNNYVALE, Calif., July 12,
2022 /PRNewswire/ -- Accuray Incorporated
(NASDAQ: ARAY) announced today that new clinical studies presented
at the 15th Congress of the International Stereotactic
Radiosurgery Society (ISRS) in Milan,
Italy reinforce the value of the company's
CyberKnife® platform in the treatment of neurological
indications with non-invasive radiosurgery. The data highlight the
benefits experienced by neurosurgeons for more than two decades,
including the ability to effectively and efficiently deliver
radiation in single and multi-fraction sessions, treat benign and
functional cases, primary brain and spine tumors and
metastases, as well as previously irradiated tumors.
"We are proud to see the impact that CyberKnife technology has
on advancing patient care, with nearly 50 abstracts presented at
the ISRS conference showcasing the system's use for non-invasive
radiosurgery treatments. The data indicate we are fulfilling our
goal to offer clinicians the tools they need to enhance the quality
of care they offer and provide additional treatment options to
their patients," said Suzanne
Winter, president and chief executive officer of
Accuray.
Ms. Winter continued, "The CyberKnife platform continues to
evolve with powerful enhancements that enable clinicians to
continue delivering extremely precise and accurate radiosurgery
treatments, while also significantly reducing treatment times,
providing a more comfortable experience for patients and enabling
medical care teams to treat more patients each day. But we are not
stopping here. Through investments in research and development and
industry partnerships we will continue to introduce best-in-class
innovations that make an incredible system even better."
New CyberKnife System Data: Helping
to Make a Clinical Difference for Patients in as little as 1 to 5
Treatments
The CyberKnife System delivers frameless radiosurgery
treatments, unlike other systems that use a fixed metal frame
attached to the patient's head to prevent movement during
treatment. It provides clinical teams with a device that maximizes
patient comfort and can deliver precision treatments in a single
session, as well as up to 5 ultra-hypofractionated treatments,
expanding access to radiosurgery to more patients. Studies shared
at the ISRS meeting indicate radiosurgery delivered with the
CyberKnife System can:
- Provide excellent local control with very low toxicity when
treating perioptic meningiomas, tumors that are challenging to
treat because of their close proximity to critical brain structures
impacting a person's vision1
- Offer a feasible and effective technique for treating patients
who have previously received radiation treatment for recurrent
primary brain tumors and metastases - indications with limited
treatment options2
- Supply an effective treatment approach for patients with
craniopharyngioma, a slow growing brain tumor, with no evidence of
long-term complications such as deterioration of visual or
neuroendocrine function3
- Provide clinical teams with an effective single fraction or
ablative option, with low toxicity, for the post-operative
treatment of brain metastases4
The CyberKnife System is the industry's only radiation delivery
system that features a linear accelerator (linac) directly mounted
onto a sophisticated robotic platform to deliver radiation therapy.
The robot maneuvers around the patient to deliver multiple beams of
radiation from thousands of angles to target the tumor or lesion.
Using advanced imaging and Accuray proprietary
Synchrony® technology, the system can see the tumor or lesion
in the brain and continually verifies its position, automatically
correcting and adapting the beam position for even the slightest
movement. For example, if the patient moves their head during
treatment, the CyberKnife® System detects this movement and
synchronizes the treatment target to the new position in real-time
delivering maximum dose directly to the tumor while minimizing dose
to surrounding health tissue, reducing the risk of many common side
effects.
Important Safety Information
For Important Safety Information please refer to
https://www.accuray.com/safety-statement.
About Accuray
Accuray is committed to expanding the powerful potential of
radiation therapy to improve as many lives as possible. We invent
unique, market-changing solutions designed to deliver radiation
treatments for even the most complex cases—while making commonly
treatable cases even easier—to meet the full spectrum of patient
needs. We are dedicated to continuous innovation in radiation
therapy for oncology, neuro-radiosurgery, and beyond, as we partner
with clinicians and administrators, empowering them to help
patients get back to their lives, faster. Accuray is headquartered
in Sunnyvale, California, with
facilities worldwide. To learn more, visit www.accuray.com or
follow us on Facebook, LinkedIn, Twitter, and YouTube.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to planned investments in
research and development and industry partnerships, new products
and innovations, clinical applications, clinical results, patient
experiences and patient outcomes. These forward-looking statements
involve risks and uncertainties. If any of these risks or
uncertainties materialize, or if any of the company's assumptions
prove incorrect, actual results could differ materially from the
results expressed or implied by these forward-looking statements.
These risks and uncertainties include, but are not limited to, the
effect of the COVID-19 pandemic on the operations of the company
and those of its customers and suppliers, the company's ability to
achieve widespread market acceptance of its products; the company's
ability to develop new products or improve existing products to
meet customers' needs; the company's ability to anticipate or keep
pace with changes in the marketplace and the direction of
technological innovation and customer demands and such other risks
identified under the heading "Risk Factors" in the company's
Quarterly Report on Form 10-Q, filed with the Securities and
Exchange Commission (the "SEC") on April 29,
2022, and as updated periodically with the company's other
filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
Media Contact
Beth Kaplan
Public Relations Director, Accuray
+1 (408) 789-4426
bkaplan@accuray.com
[1] ORAL PRESENTATIONS Skull-base Societies Session:
Meningiomas; OP14 PERIOPTIC MENINGIOMAS TREATED WITH CYBERKNIFE
RADIOSURGERY (1 - 5 SESSIONS): CLINICAL RESULTS. Morena SALLABANDA
(Madrid, Spain), Kita SALLABANDA.
https://isrscongress.org/real-time-programme-expanded/
[2] 01. EPOSTERS - BRAIN – MALIGNANT; P023 Re-irradiation
of relapsed intracranic lesions with stereotactic radiotherapy: a
monoinstitutional experience. Stefano Lorenzo VILLA (Milan, Italy), Chiara Lucrezia DEANTONI,
Andrei FODOR, Roberta TUMMINERI, Flavia ZERBETTO, Sara BROGGI,
Jessica SADDI, Barbara LONGOBARDI, Antonella DEL VECCHIO, Italo
DELL'OCA, Nadia Gisella DI MUZIO.
https://isrscongress.org/eposters/
[3] 02. EPOSTERS - BRAIN – BENIGN; P089 Long term results
in stereotactic radiosurgery for craniopharyngioma:
monoinstitutional experience. Sara MORLINO (Milano, Italy), Marcello MARCHETTI, Valentina
PINZI, Irene CANE, Maria Luisa FUMAGALLI, Laura FARISELLI.
https://isrscongress.org/eposters/
[4] 01. EPOSTERS - BRAIN – MALIGNANT; P034 Stereotactic
radiosurgery (SRS) and fractionated stereotactic radiosurgery
(fSRS) as adjuvant treatment for resected brain metastases (BMs): a
single-center series. Valentina PINZI (Milan, Italy), Anna ROMEO, Marcello MARCHETTI,
Sara MORLINO, Irene TRAMACERE, Laura FARISELLI.
https://isrscongress.org/eposters/
View original content to download
multimedia:https://www.prnewswire.com/news-releases/accuray-cyberknife-system-real-world-data-and-clinical-studies-show-benefits-in-treatment-of-neurological-indications-301583528.html
SOURCE Accuray Incorporated